MuscleBlaze’s owner burned through ₹330 crore (about $34.4 million) in a single year even as its whey-protein tubs sold in more than a hundred Indian cities. Four years later, the same company posted a ₹120 crore profit and is now weighing a stock-market listing that could raise up to ₹3,800 crore.
The brand most gym-goers know only for scoop-sized tubs and cricket-adjacent ad campaigns sits inside a much bigger, quieter machine: a Gurugram company called Bright Lifecare Private Limited, doing business as HealthKart, which owns eight nutrition brands and runs both an e-commerce operation and 250 physical stores. MuscleBlaze is its flagship, not its whole story — and the swing from near-decade-long losses to profit explains why a company that twice nearly ran out of road is now the one filing paperwork for an IPO.
Quick facts
| Company | MuscleBlaze, a brand owned and operated by Bright Lifecare Private Limited (doing business as HealthKart) |
| Founded | HealthKart founded 2011; MuscleBlaze launched as an in-house brand in 2012 |
| Founder(s) | Sameer Maheshwari (Founder-CEO); co-founder Prashant Tandon exited in April 2015 to build 1mg |
| Businesses | Eight in-house nutrition brands (MuscleBlaze, HKVitals, TrueBasics, Gritzo, The Protein Zone, bGreen, Nouriza and one more) sold via HealthKart.com, marketplaces and owned retail |
| Latest FY revenue | ₹1,313 crore, FY25 (Bright Lifecare/HealthKart, consolidated) |
| Latest FY profit/loss | Net profit ₹120 crore, FY25 |
| Listed | Private; weighing an IPO, reportedly targeting a listing by end of 2027 |
| Market value / last valuation | About $500 million, as of a November 2024 secondary funding round |
| Key shareholders / CEO | Sameer Maheshwari (Founder-CEO); investors including ChrysCapital, Motilal Oswal Alternates, A91 Partners, Temasek and Sofina |
What they do
MuscleBlaze sells whey protein, mass gainers, pre-workout formulas, BCAAs, creatine and fitness foods to gym-goers, home-fitness users and casual protein buyers across price tiers, from entry-level tubs to premium isolates. It is sold direct-to-consumer through MuscleBlaze.com and HealthKart.com, through marketplaces such as Amazon and Flipkart, and through 250 physical HealthKart stores spread across 111 Indian cities as of June 2026, according to trade coverage of the company’s retail expansion. MuscleBlaze is the flagship of a wider family: its parent, Bright Lifecare, builds separate in-house brands for other buyer groups rather than stretching one brand across every category — HKVitals for everyday vitamins and general wellness, TrueBasics for science-positioned supplements, Gritzo for children’s nutrition, The Protein Zone as a value-tier protein label, and bGreen and Nouriza for plant-based and other adjacent nutrition needs.
The origin
Sameer Maheshwari spent roughly twelve years in the United States after graduating from IIT in 1997, working in technology before an MBA at Harvard Business School and a stint in investment banking. In 2011 he moved back to India with Prashant Tandon, a batchmate with a complementary healthcare background, convinced that India’s health and wellness market was being held back by one basic problem: buyers could not trust what they were being sold. They started HealthKart as an online platform for health, wellness and fitness products, initially reselling other brands’ stock. It did not take long to discover that reselling was itself the weak point — resellers had no real control over whether the protein powder, vitamins or supplements moving through their supply chain were genuine. HealthKart’s answer, launched in 2012, was to stop relying only on third-party brands and build its own: MuscleBlaze, an in-house sports-nutrition label the company could manufacture, test and stand behind directly, rather than merely list.
The struggle years
The first serious fracture came from inside a success. Sometime around 2014, an internal experiment called HealthKart Plus — a mobile app that let users compare medicine prices — went viral and exposed a pharmacy opportunity far bigger than anyone at the company had planned for. Nutrition and pharmacy could not be built with the same urgency under one roof, and in April 2015 the founders split the company: Tandon carved the pharmacy business out as 1mg, and Maheshwari kept HealthKart, now stripped down to nutrition alone, four years after starting from scratch and effectively forced to start again on strategy.
The financial toll of rebuilding around nutrition only, and then scaling it, took years to show up as anything other than losses. In FY22, the business booked revenue of just ₹490.8 crore against a net loss of ₹330.1 crore, an EBITDA margin of roughly minus 63%, meaning it lost more than half a rupee at the operating level for every rupee it took in, according to Inc42’s review of the company’s regulatory filings. FY23 looked like progress on the surface — revenue jumped 70% to ₹832.4 crore — but the company still lost ₹164.7 crore that year, and procurement costs alone rose 80% to ₹430.3 crore, faster than revenue itself; growth was being bought with cash the company did not yet have coming back in margin. Running alongside the balance-sheet strain was a credibility problem baked into the whole category: independent lab tests circulating in India’s fitness press for years had questioned whether protein-powder brands, MuscleBlaze included, delivered the protein content printed on the label. The company’s response, in August 2022, was to design and ship its own home-use authenticity test kit, MB ProCheck, so customers could check a tub’s protein content themselves — an admission, in effect, that trust in the entire product category, not just competitors’ products, needed rebuilding.
The turning point
The pivot was not a funding round; it was the year the operating business finally worked. Going into FY24, HealthKart carried the weight of a FY23 loss of ₹164.7 crore even after a strong revenue year — a company thirteen years old that had never closed a full year in the black. FY24 broke that pattern: revenue crossed ₹1,000 crore for the first time, closing at ₹1,021 crore, and the company reported its first full-year EBITDA profitability, ending the year with a net profit of about ₹37 crore. That operating proof point, not a pitch deck, is what unlocked the next round: in November 2024, HealthKart raised $153 million in an all-secondary transaction at a valuation of about $500 million, up from roughly $350 million before the deal. Peak XV Partners, formerly Sequoia India, used the round to fully exit, turning shares it had originally bought for under $30 million into a sale worth about $120 million — a return built entirely on the company finally proving it could make money, not just grow revenue.
The money behind it
- Total raised: roughly $221 million across at least eight funding rounds from more than 20 investors, per Tracxn’s tally of HealthKart’s cap table.
- Series G, May 2019: $25 million led by Sofina, the Brussels-based investor’s first check into the company — the capital pushed HealthKart from a single sports-nutrition bet into a deliberate multi-brand nutrition portfolio and funded faster offline-store expansion.
- Series H, November 2022: Temasek and A91 Partners made their first investments in this round, part of a wider raise alongside Kae Capital that deepened institutional ownership ahead of any future listing.
- Secondary round, November 2024: $153 million, all-secondary, co-led by ChrysCapital and Motilal Oswal Alternates with participation from A91 Partners and Neo Group, advised by Avendus Capital; valued the company at about $500 million and funded the company’s first employee stock buyback, worth roughly ₹55 crore.
- Latest valuation: about $500 million, based on the November 2024 round — the company’s most recently disclosed mark, as reported independently by TechCrunch and Business Standard.
- Next step, reported September 2026: HealthKart is weighing an IPO of $300-400 million (about ₹2,800-3,800 crore), combining fresh primary capital with a secondary sale by existing investors, and is said to be targeting a listing by the end of 2027, per Mint’s reporting.
How it makes money
HealthKart earns almost entirely by manufacturing and selling its own branded nutrition products, rather than by taking a cut as a pure marketplace for other people’s brands. In FY25, product sales made up 97% of revenue at ₹1,277 crore, versus just 3%, or ₹36 crore, from services such as in-store nutrition counselling. It sells through three channels at once — its own website, marketplaces including Amazon and Flipkart, and its own network of physical stores — and has run its own manufacturing facility since 2019 rather than depending only on third-party contract manufacturers, which keeps more of the margin in-house instead of paying it out to a supplier.
- What people get wrong, part one: MuscleBlaze is not the company. It is one of eight in-house brands sitting under Bright Lifecare’s HealthKart platform, alongside HKVitals, TrueBasics, Gritzo, The Protein Zone, bGreen and Nouriza.
- What people get wrong, part two: it is not an online-only D2C label. HealthKart runs 250 physical stores across 111 cities that double as consultation counters, a channel built specifically to convert first-time buyers who want to touch a product or ask a question before paying.
- Where the margin actually sits: cost of materials was ₹623 crore, or 49% of FY25’s total expenses, and advertising was the fastest-rising cost line at ₹263 crore, up 39% year-on-year, while employee costs fell 5% to ₹115 crore — the FY24-to-FY25 profit gain came from spending smarter on production and marketing, not from cutting headcount.
The numbers
| Fiscal year | Revenue (₹ crore) | Net profit / (loss) (₹ crore) |
|---|---|---|
| FY22 | 491 | (330) |
| FY23 | 832 | (165) |
| FY24 | 1,021 | 37 |
| FY25 | 1,313 | 120 |
Figures for FY22 and FY23 are per Inc42’s review of the company’s regulatory filings; FY24 and FY25 are per Entrackr’s review of the same filings. A standalone Bright Lifecare Private Limited filing cited separately by CEO India Magazine puts the FY23-to-FY24 swing at a wider ₹164.73 crore loss to ₹38.33 crore profit — the small gap between sources traces to standalone-versus-consolidated accounting scope, not a dispute over direction.
- Cost efficiency: the company spent ₹0.97 to generate every rupee of revenue in FY25, down from ₹1.01 in FY24.
- Cost of materials: ₹623 crore in FY25, up 26% year-on-year, and consistently the single largest expense line across every year on record.
- Advertising spend: ₹263 crore in FY25, up 39% year-on-year — the fastest-growing cost category even as overall expenses rose only 23%.
- FY25 EBITDA margin came in at 6.02% and return on capital employed at 5.45%, both broadly in line with FY24’s 6.51% EBITDA margin and 5.6% ROCE, even as absolute profit nearly tripled — a sign that scale, not margin expansion, is doing most of the work.
Where the money comes from
- Product sales: ₹1,277 crore, 97% of FY25 revenue, up 29% year-on-year.
- Services (in-store counselling and related offerings): ₹36 crore, 3% of FY25 revenue, up 16% year-on-year — small, but growing.
- Retail footprint: 250 stores across 111 cities as of June 2026, up from 130-plus stores across 40 cities reported by Inc42 in December 2022 — roughly tripling city coverage in under four years.
- Channel concentration, company-stated: MuscleBlaze told the trade press in November 2023 that it held about 55% share of India’s direct-to-consumer protein-powder market and roughly 35% share specifically on Amazon India — a company-reported figure, not an independently audited one.
- The surprise: for a brand famous for one product category, HealthKart’s actual growth engine is diversification — seven brands beyond MuscleBlaze and a fast-scaling store network mean the business is no longer a single-product bet, even though MuscleBlaze remains the name most buyers recognise.
The risks
- Category-wide authenticity and regulatory risk: independent testing controversies have repeatedly questioned protein-content claims across Indian whey brands, serious enough that MuscleBlaze built and shipped its own MB ProCheck home-test kit in August 2022 just to reassure buyers — any adverse finding under FSSAI food-safety standards could damage the flagship brand’s core promise directly.
- Marketing-spend dependency: advertising has grown faster than, or in line with, revenue in most years on record, rising 39% to ₹263 crore in FY25 against 29% revenue growth — a chunk of recent profitability rests on continuing to outspend rivals for visibility rather than on pricing power alone.
- Marketplace and competitive exposure: MuscleBlaze’s own reported 35% share on Amazon India sits on a shelf the company does not control, next to international entrants such as Optimum Nutrition and Dymatize that HealthKart itself lists and sells — success rented on someone else’s platform is never fully defensible, and domestic challengers in the same aisle add further pressure.
The takeaway
The lesson sitting inside MuscleBlaze’s numbers is not the usual one about scaling fast. It is about what a company does when the thing damaging its business is the credibility of its own product category, not a competitor. HealthKart could have simply advertised harder to talk over the doubts about protein-powder authenticity; instead it spent money building a test kit that let a customer prove the company right or wrong in their own kitchen, a decision that cost money and quietly admitted a real problem existed before insisting it was solved. That willingness to invest in disproving a doubt, rather than only marketing past it, sits underneath the same years in which losses finally turned into profit. A category built on trust problems is rarely fixed by a bigger ad budget; it is fixed by making the proof cheaper for the customer to get than the doubt was to hold onto.
Frequently asked questions
Who owns MuscleBlaze?
MuscleBlaze is a brand owned and operated by Bright Lifecare Private Limited, which does business as HealthKart and is headquartered in Gurugram. It was founded by Sameer Maheshwari, who remains Founder-CEO; co-founder Prashant Tandon exited in 2015 to build the pharmacy platform 1mg.
Is MuscleBlaze’s parent company profitable?
Yes, as of the most recent reported year. Bright Lifecare/HealthKart posted a consolidated net profit of about ₹120 crore on revenue of ₹1,313 crore in FY25, according to Entrackr’s review of the company’s filings, following a first-ever profitable year in FY24 after several years of losses, including a ₹330.1 crore loss in FY22.
How much funding has HealthKart raised, and who are its investors?
HealthKart has raised roughly $221 million across at least eight rounds from more than 20 investors, per Tracxn, including Sofina, Peak XV Partners (fully exited in 2024), Temasek, A91 Partners, Kae Capital, ChrysCapital and Motilal Oswal Alternates. Its most recent disclosed valuation is about $500 million, from a $153 million secondary round in November 2024.
Is MuscleBlaze or HealthKart planning an IPO?
HealthKart is reported to be weighing an IPO of $300-400 million, or roughly ₹2,800-3,800 crore, combining new capital with a secondary sale by existing shareholders, with a targeted listing by the end of 2027, according to Mint’s September 2026 reporting. No listing date or exchange had been confirmed at the time of writing.
What is MuscleBlaze’s market share in India?
MuscleBlaze told the trade press in November 2023 that it held about 55% share of India’s direct-to-consumer protein-powder market and roughly 35% share on Amazon India specifically. These are company-reported figures rather than independently audited market-research numbers, so they should be read as MuscleBlaze’s own claim about its position, not a verified industry count.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr, “Healthkart’s revenue nears Rs 1,400 Cr in FY25; profit triples,” 2026.
- Entrackr, “HealthKart reports Rs 1,021 Cr revenue and Rs 37 Cr PAT in FY24,” December 2024.
- Inc42, “HealthKart’s FY23 Sales Surge 70% To Cross INR 800 Cr Mark, Loss Halves,” 2023.
- Inc42, “Healthkart Turns Profitable, Posts INR 38 Cr PAT In FY24,” 2024.
- CEO India Magazine, “HealthKart Achieves Profitability in FY24 with Strong Revenue Growth and Improved Margins,” 2024.
- TechCrunch, “India’s HealthKart raises $153 million in new funding,” 18 November 2024.
- Business Standard, “HealthKart raises $153 million from ChrysCapital, Motilal Oswal Alternates,” November 2024.
- Mint, “HealthKart weighs $300-400 mn IPO,” September 2026.
- YourStory, “[Funding alert] Armed with fresh funding of $25M led by Sofina,” May 2019.
- Inc42, “130+ Stores, 1K+ Brands, 40 Cities: How HealthKart Is Addressing India’s Healthy Habits,” December 2022.
- D2C Insider Pulse, “HealthKart Crosses 250 Stores Across 111 Cities, Strengthening Its Omnichannel Leadership in India’s Wellness Market,” June 2026.
- Entrepreneur India, “The Healthtech Hero,” profile of Sameer Maheshwari.
- NutraIngredients, “MuscleBlaze develops test kit for consumers to verify protein powder authenticity,” August 2022.
- NutraIngredients/DairyReporter, “Kick out the cheats: MuscleBlaze gains 10% market share a year after launching whey protein test kits,” November 2023.
- HealthKart.com Connect, “11 Years of HealthKart: A Journey Worth Celebrating,” company timeline.
- Ken Research, “India Protein Gap Built HealthKart’s ₹1313 Cr Profitable…” review of FY25 filings.
- Tracxn, HealthKart company and funding profile, 2026.
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.